Studies using SI-2, a specific small-molecule inhibitor of SRC-3, also found that in breast cancer, SI-2 not only reduces the number of Tregs but also effectively increases the number of CD4+ T, CD8+ T, and CD56+ NK cells, as well as the secretion of IFN-γ 126. Here, CD8A is linked to breast cancer.